A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...
Researchers at UChicago have developed a nanoparticle system that can effectively deliver mRNA to insulin-producing cells, protecting them from the body’s autoimmune response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results